Assessing the Benefits and Risks of Amantadine for Irritability and Aggression after Traumatic Brain Injury

金刚烷胺 易怒 安慰剂 不利影响 医学 随机对照试验 心理学 需要伤害的数量 心理干预 精神科 需要治疗的数量 内科学 药理学 替代医学 病理 焦虑
作者
Flora M. Hammond,Ross Zafonte,Mark Sherer,Kathleen Bell,Jennifer Bogner,James F. Malec,Qing Tang,Jeong Hoon Jang
出处
期刊:Archives of Physical Medicine and Rehabilitation [Elsevier BV]
卷期号:102 (10): e5-e5
标识
DOI:10.1016/j.apmr.2021.07.402
摘要

Research Objectives To explore the benefits versus harms of amantadine in the treatment of irritability and aggression. Design Parallel-group, randomized, double-blind, placebo-controlled trial of amantadine versus placebo. Setting Outpatient. Participants 168 individuals with chronic TBI and irritability (amantadine n=82 versus placebo n=86). Interventions Amantadine 100 mg or placebo equivalent two times daily. Main Outcome Measures Number-Needed-To-Treat (NNT) and Number-Needed-to-Harm (NNH). NNT was calculated using number of individuals with improvement as indicated by Clinical Global Impressions – Global Improvement scale. NNH was calculated using 3 definitions of adverse outcome: number of participants with GI indicating worsening, number of participants with serious adverse events, and number of participants with adverse events. Results Based on clinician ratings, for every 6 patients treated with amantadine, 1 patient more than placebo would be expected to improve. More participants in the placebo group worsened than in the amantadine group. For every 27 patients treated, 1 more than the placebo would be expected to experience serious adverse events. More participants in the placebo group experienced adverse events of any severity than in the amantadine group. Conclusions Clinician ratings suggest moderate benefit with low risk to appropriately selected patients. Thus, amantadine should be considered a treatment option for the experienced brain injury clinician. These data may support treatment decisions when a pharmaceutical agent is being considered to control irritability/aggression. Author(s) Disclosures Dr. Hammond serves on the Avanir Scientific Advisory Committee. To explore the benefits versus harms of amantadine in the treatment of irritability and aggression. Parallel-group, randomized, double-blind, placebo-controlled trial of amantadine versus placebo. Outpatient. 168 individuals with chronic TBI and irritability (amantadine n=82 versus placebo n=86). Amantadine 100 mg or placebo equivalent two times daily. Number-Needed-To-Treat (NNT) and Number-Needed-to-Harm (NNH). NNT was calculated using number of individuals with improvement as indicated by Clinical Global Impressions – Global Improvement scale. NNH was calculated using 3 definitions of adverse outcome: number of participants with GI indicating worsening, number of participants with serious adverse events, and number of participants with adverse events. Based on clinician ratings, for every 6 patients treated with amantadine, 1 patient more than placebo would be expected to improve. More participants in the placebo group worsened than in the amantadine group. For every 27 patients treated, 1 more than the placebo would be expected to experience serious adverse events. More participants in the placebo group experienced adverse events of any severity than in the amantadine group. Clinician ratings suggest moderate benefit with low risk to appropriately selected patients. Thus, amantadine should be considered a treatment option for the experienced brain injury clinician. These data may support treatment decisions when a pharmaceutical agent is being considered to control irritability/aggression.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Tqun完成签到,获得积分10
刚刚
you完成签到 ,获得积分10
1秒前
lfy完成签到,获得积分10
1秒前
小毛竹完成签到 ,获得积分10
5秒前
DW的应助被WinStar采纳,获得10
5秒前
智文完成签到 ,获得积分10
7秒前
8秒前
从容棉花糖完成签到,获得积分10
9秒前
Akim的应助被俏皮诺言采纳,获得10
11秒前
junjun2011完成签到 ,获得积分10
11秒前
烟花弥漫完成签到 ,获得积分10
13秒前
明朗完成签到 ,获得积分0
14秒前
about发布了新的文献求助10
14秒前
默默白桃完成签到 ,获得积分10
16秒前
我爱自由民权完成签到,获得积分10
18秒前
阳光雅蕊完成签到,获得积分10
18秒前
hugefrog完成签到,获得积分10
20秒前
wxf666完成签到 ,获得积分10
20秒前
HelloBOB完成签到 ,获得积分10
22秒前
PORCO完成签到,获得积分10
27秒前
英勇雅琴完成签到 ,获得积分10
27秒前
dingo完成签到,获得积分10
30秒前
阿南完成签到 ,获得积分0
31秒前
朴素傲松完成签到,获得积分10
31秒前
追寻微笑完成签到 ,获得积分10
32秒前
taotao完成签到 ,获得积分10
32秒前
zilicai的应助被十二采纳,获得20
32秒前
duktig完成签到 ,获得积分10
33秒前
hooqueen完成签到 ,获得积分10
33秒前
about完成签到,获得积分10
34秒前
韩寒123完成签到,获得积分10
35秒前
特特特特特完成签到,获得积分10
37秒前
bobinson完成签到,获得积分10
37秒前
乐观的星月完成签到 ,获得积分0
41秒前
Hello的应助被liugm采纳,获得10
43秒前
小菀儿完成签到 ,获得积分10
44秒前
Royzeng完成签到 ,获得积分10
48秒前
止咳宝完成签到,获得积分10
48秒前
科研通AI6.3的应助被单身的紊采纳,获得10
50秒前
JonyJie完成签到,获得积分10
50秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190389
求助须知:如何正确求助?哪些是违规求助? 9577468
关于积分的说明 21852623
捐赠科研通 7789041
什么是DOI,文献DOI怎么找? 3436369
关于科研通互助平台的介绍 2560180
邀请新用户注册赠送积分活动 2482995